Abstract
Lysophosphatidic acid (LPA), via interaction with its G-protein coupled receptors, is involved in various pathological conditions. Extracellular LPA is mainly produced by the enzyme autotaxin (ATX). Using fibroblast-like synoviocytes (FLS) isolated from synovial tissues of patients with rheumatoid arthritis (RA), we studied the expression profile of LPA receptors, LPA-induced cell migration, and interleukin (IL)-8 and IL-6 production. We report that FLS express LPA receptors LPA1-3. Moreover, exogenously applied LPA induces FLS migration and secretion of IL-8/IL-6, whereas the LPA3 agonist l-sn-1-O-oleoyl-2-methyl-glyceryl-3-phosphothionate (2S-OMPT) stimulates cytokine synthesis but not cell motility. The LPA-induced FLS motility and cytokine production are suppressed by LPA1/3 receptor antagonists diacylglycerol pyrophosphate and (S)-phosphoric acid mono-(2-octadec-9-enoylamino-3-[4-(pyridine-2-ylmethoxy)-phenyl]-propyl) ester (VPC32183). Signal transduction through p42/44 mitogen-activated protein kinase (MAPK), p38 MAPK, and Rho kinase is involved in LPA-mediated cytokine secretion, whereas LPA-induced cell motility requires p38 MAPK and Rho kinase but not p42/44 MAPK. Treatment of FLS with tumor necrosis factor-α (TNF-α) increases LPA3 mRNA expression and correlates with enhanced LPA- or OMPT-induced cytokine production. LPA-mediated superproduction of cytokines by TNF-α-primed FLS is abolished by LPA1/3 receptor antagonists. We also report the presence of ATX in synovial fluid of patients with RA. LPA1/3 receptor antagonists and ATX inhibitors reduce the synovial fluid-induced cell motility. Together the data suggest that LPA1 and LPA3 may contribute to the pathogenesis of RA through the modulation of FLS migration and cytokine production. The above results provide novel insights into the relevance of LPA receptors in FLS biology and as potential therapeutic targets for the treatment of RA.
Footnotes
-
This project is supported by research grants from Canadian Institutes of Health Research (S.G.B.) and the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research (T.C.). C.Z. is the recipient of the Canadian Arthritis Network Post-Doctoral Fellowship Award. G.D.P. acknowledges National Institutes of Health grant NS29632 for support.
-
ABBREVIATIONS: RA, rheumatoid arthritis; LPA, lysophosphatidic acid; FLS, fibroblast-like synoviocyte; ATX, autotaxin; IL, interleukin; TNF-α, tumor necrosis factor-α; MAPK, mitogen-activated protein kinase; VPC32183, (S)-phosphoric acid mono-(2-octadec-9-enoylamino-3-[4-(pyridine-2-ylmethoxy)-phenyl]-propyl) ester; 2S-OMPT, l-sn-1-O-oleoyl-2-methyl-glyceryl-3-phosphothionate; DGPP, diacylglycerol pyrophosphate; lyso-PLD, lysophospholipase D; LPC, lysophosphatidylcholine; ccPA, carbacyclic phosphatidic acid; ELISA, enzyme-linked immunosorbent assay; JNK, c-Jun NH2-terminal kinase; ATF-2, activating transcription factor-2; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-polymerase chain reaction; bp, base pair; PAGE, polyacrylamide gel electrophoresis; JGW-8, C20H39NaBrO6P; XY-44, C22H40O4PSNa; PD98059, 2′-amino-3′-methoxyflavone; SB203580, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; SP600125, anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone; Y27632, N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide dihydrochloride.
- Received May 17, 2007.
- Accepted November 14, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
